 Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 17 | 22 | | 1997 | 4 | 10 | 14 | | 1998 | 0 | 13 | 13 | | 1999 | 2 | 12 | 14 | | 2000 | 2 | 25 | 27 | | 2001 | 4 | 28 | 32 | | 2002 | 0 | 28 | 28 | | 2003 | 3 | 12 | 15 | | 2004 | 3 | 19 | 22 | | 2005 | 4 | 14 | 18 | | 2006 | 3 | 24 | 27 | | 2007 | 1 | 10 | 11 | | 2008 | 4 | 15 | 19 | | 2009 | 4 | 12 | 16 | | 2010 | 4 | 23 | 27 | | 2011 | 5 | 16 | 21 | | 2012 | 6 | 9 | 15 | | 2013 | 8 | 10 | 18 | | 2014 | 5 | 9 | 14 | | 2015 | 10 | 12 | 22 | | 2016 | 6 | 11 | 17 | | 2017 | 7 | 8 | 15 | | 2018 | 2 | 8 | 10 | | 2019 | 4 | 3 | 7 | | 2020 | 3 | 7 | 10 | | 2021 | 5 | 5 | 10 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 5 | 6 | | 2024 | 2 | 0 | 2 | | 2025 | 6 | 3 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Lentz RW, Lang J, Pitts TM, Blatchford P, Hu J, Jordan KR, Van Bokhoven A, Bagby SM, Dominguez ATA, Binns CA, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer K, Scott AJ, Boland PM, Hochster HS, Messersmith WA. Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer. Cancer Res Commun. 2025 Nov 01; 5(11):2039-2052.
-
Derington CG, Sarwal A, Wei G, Hartsell SE, Throolin M, Singh R, Nevers MR, Zhang C, Katkam N, Takyi A, Chakravartula AR, Babu P, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Shen J, Beddhu S. Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes. JAMA Netw Open. 2025 Oct 01; 8(10):e2537297.
-
McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Kopec G, Meyer G, Olsson KM, Fu W, Shi Y, Miller B, Kim SS, Mackenzie HS, Brambatti M, Patel MJ, Koglin J, Cornell AG, Humbert M. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 2025 Oct 23; 393(16):1599-1611.
-
Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Humbert M, McLaughlin VV, Waxman AB, Manimaran S, Mikhailova E, Reddy M, Lau A, de Oliveira Pena J, Souza R. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025 Jul; 66(1).
-
Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M. Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR). Am J Respir Crit Care Med. 2025 Jun; 211(6):1028-1037.
-
McMahon C, Raddi MG, Mohan S, Santini V. New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473654.
-
Hoeper MM, Gomberg-Maitland M, Badesch DB, Gibbs JSR, Grünig E, Kopec G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Manimaran S, Wang X, Miller B, Cornell AG, de Oliveira Pena J, Ghofrani HA, Humbert M. Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. Eur Respir J. 2025 May; 65(5).
-
Kim TM, Lakhani NJ, Soumerai J, Kamdar M, Gainor JF, Messersmith W, Fanning P, Guan S, Jin F, Forgie A, Wan HI, Pons J, Randolph SS, Kim WS. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. Haematologica. 2025 Sep 01; 110(9):2102-2112.
-
Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025 May 29; 392(20):1987-2000.
-
Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, Turfanda I, Cox DA. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024 Sep 01; 47(9):1617-1621.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|